| Mesenchymal stem cell-based therapy V Mundra, IC Gerling, RI Mahato Molecular pharmaceutics 10 (1), 77-89, 2013 | 163 | 2013 |
| Nanoparticle-mediated drug delivery for treating melanoma V Mundra, W Li, RI Mahato Nanomedicine 10 (16), 2613-2633, 2015 | 66 | 2015 |
| Micellar formulation of indocyanine green for phototherapy of melanoma V Mundra, Y Peng, S Rana, A Natarajan, RI Mahato Journal of Controlled Release 220, 130-140, 2015 | 57 | 2015 |
| Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling A Pratap, S Singh, V Mundra, N Yang, R Panakanti, JD Eason, RI Mahato Journal of drug targeting 20 (9), 770-782, 2012 | 51 | 2012 |
| Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis V Kumar, V Mundra, RI Mahato Pharmaceutical research 31, 1158-1169, 2014 | 50 | 2014 |
| Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice V Kumar, V Mundra, Y Peng, Y Wang, C Tan, RI Mahato Theranostics 8 (15), 4033, 2018 | 42 | 2018 |
| Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent V Mundra, Y Lu, M Danquah, W Li, DD Miller, RI Mahato Pharmaceutical research 29, 3064-3074, 2012 | 23 | 2012 |
| Design of nanocarriers for efficient cellular uptake and endosomal release of small molecule and nucleic acid drugs: learning from virus V Mundra, RI Mahato Frontiers of Chemical Science and Engineering 8, 387-404, 2014 | 22 | 2014 |
| Genetically modified human bone marrow derived mesenchymal stem cells for improving the outcome of human islet transplantation V Mundra, H Wu, RI Mahato PLoS One 8 (10), e77591, 2013 | 22 | 2013 |
| Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma V Mundra, Y Peng, V Kumar, W Li, DD Miller, RI Mahato Drug delivery and translational research 5, 199-208, 2015 | 18 | 2015 |
| Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma R Yang, G Mondal, RA Ness, K Arnst, V Mundra, DD Miller, W Li, ... Journal of Controlled Release 249, 32-41, 2017 | 12 | 2017 |
| Preliminary safety of a Bcl-2 Inhibitor, Bgb-11417, in patients with relapsed/refractory multiple myeloma harboring t (11, 14): A non-randomized, open-label, phase 1b/2 study H Quach, R Rajagopal, A Spencer, M Low, D Kazandjian, R Crescenzo, ... Blood 140 (Supplement 1), 7269-7271, 2022 | 4 | 2022 |
| Methods to Separate, Characterize, and Encapsulate Drug Molecules into Exosomes for Targeted Delivery and Treatment of Glioblastoma Y Nguyen, S Kaur, H Shim, V Mundra, V Nadithe Nanotherapy for Brain Tumor Drug Delivery, 259-279, 2021 | 1 | 2021 |
| Preliminary Safety of Bcl-2 Inhibitor BGB-11417 in Relapsed/Refractory Multiple Myeloma Harboring t (11, 14): Phase 1b/2 Study R Crescenzo, H Quach, R Rajagopal, A Spencer, M Low, D Kazandijan, ... British Journal of Haematology, 63-63, 2023 | | 2023 |
| AACP REPORT New Investigator Award Recipient Poster Abstracts Presented at the 121st Virtual Annual Meeting of the American Association of Colleges of Pharmacy, July 13-31, 2020 AL Pasternak, A Lauren American Journal of Pharmaceutical Education 84 (6), 8231, 2020 | | 2020 |
| Polymeric Nanocarriers for Treatment of Melanoma and Genetically Modified Mesenchymal Stem Cells to Improve Outcome of Islet Transplantation V Mundra | | 2015 |
| Preliminary Safety of Bcl-2 Inhibitor BGB-11417 in Relapsed/Refractory Multiple Myeloma Harboring t (11, 14): Phase 1b/2 Study D Kazandjian, H Quach, A Spencer, M Low, R Crescenzo, C Du, S Patel, ... | | |
Ram I MahatoProfessor and Chair, Department of Pharmaceutical Sciences, University of Nebraska Medical CenterVerified email at unmc.edu
